Yale Cancer Center was founded in 1974 as a result of an act of Congress in 1971, which declared the nation's "war on cancer".

During the past decade, Yale Cancer Center conducted 195 clinical trials. In the 10-year time frame, 195 clinical trials started and 92 clinical trials were completed, i.e. on average, 47.2% percent of trials that started reached the finish line to date. In the past 5 years, 78 clinical trials started and 60 clinical trials were completed. i.e. 76.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Yale Cancer Center" #1 sponsor was "Yale University" with 46 trials, followed by "Children's Oncology Group" with 39 trials sponsored, "Hoffmann-La Roche" with 22 trials sponsored, "Celgene" with 15 trials sponsored and "Genentech, Inc." with 15 trials sponsored. Other sponsors include 234 different institutions and companies that sponsored additional 138 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Yale Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 93 trials as a collaborator, "Merck Sharp & Dohme LLC" with 14 trials as a collaborator, "Bayer" with 5 trials as a collaborator, "Bristol-Myers Squibb" with 5 trials as a collaborator and "AstraZeneca" with 4 trials as a collaborator. Other collaborators include 148 different institutions and companies that were collaborators in the rest 117 trials.

According to Clinical.Site data, the most researched conditions in "Yale Cancer Center" are "Breast Cancer" (32 trials), "Lymphoma" (22 trials), "Leukemia" (17 trials), "Prostate Cancer" (15 trials) and "Colorectal Cancer" (13 trials). Many other conditions were trialed in "Yale Cancer Center" in a lesser frequency.

Most popular intervention types in "Yale Cancer Center" are "Drug" (323 trials), "Biological" (66 trials), "Radiation" (43 trials), "Procedure" (35 trials) and "Other" (18 trials). Other intervention types were less common.

The name of intervention was led by "cyclophosphamide" (25 trials), "radiation therapy" (25 trials), "filgrastim" (21 trials), "Pembrolizumab" (20 trials) and "etoposide" (19 trials). Other intervention names were less common.

The vast majority of trials in "Yale Cancer Center" are 333 trials for "All" genders, 22 trials for "Female" genders and 17 trials for "Male" genders.

Currently, there are NaN active trials in "Yale Cancer Center". undefined are not yet recruiting, 78 are recruiting, 41 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 203 completed trials in Yale Cancer Center, 1 suspended trials, and 41 terminated clinical trials to date.

Out of the total trials that were conducted in Yale Cancer Center, 144 "Phase 1" clinical trials were conducted, 162 "Phase 2" clinical trials and 86 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 11 trials that are defined as “Not Applicable".

Yale Cancer Center has several departments that took part in Clinical trials: "Smilow Cancer Hospital Phase 1 Unit" - 5 trials, "Yale Hemophilia Treatment Center" - 2 trials